Thermostable FGF-2 Mutant K128N for Stem Cell Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for culturing human pluripotent stem cells require high concentrations of FGF-2, which are costly and inefficient, and the functional differences between FGF proteins are not well understood, particularly regarding their affinity to FGF receptors and tissue-specific expression.
Innovation Solution
A thermostable FGF-2 polypeptide with a K128N substitution, which maintains biological activity at lower concentrations and is more stable than wild-type FGF-2, is used in culture media to support pluripotency and self-renewal of human pluripotent stem cells, potentially replacing wild-type FGF-2 in somatic cell reprogramming.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentrations of wild-type FGF-2 are used to maintain pluripotency, then pluripotency maintenance is effective, but culture cost increases and efficiency decreases
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of FGF-2 (specifically K128N substitution) to alter its thermal stability parameter. This mutation increases the protein's resistance to thermal degradation, allowing it to maintain biological activity at lower concentrations over extended periods, thereby reducing the quantity of substance needed while maintaining effectiveness
Solution Approach 2:
The patent uses partial action by implementing a single point mutation (K128N) rather than extensive structural modifications. This minimal change partially alters the protein's properties to achieve enhanced thermostability, sufficient to maintain pluripotency at reduced concentrations without requiring complete redesign of the FGF-2 molecule
2Reliability
If high concentrations of FGF-2 are used in culture media, then pluripotency is maintained, but culture efficiency and cost-effectiveness deteriorate
Solution Approach 1:
By changing the thermal stability parameter of FGF-2 through the K128N mutation, the protein remains active longer in culture media without degradation. This extends the effective duration of action, allowing lower concentrations to achieve the same cumulative biological effect, thereby improving culture efficiency and reducing costs
3Reliability
If wild-type FGF-2 is used, then biological activity is achieved, but thermal stability is insufficient leading to rapid degradation
Solution Approach 1:
The patent directly addresses this contradiction by changing the thermal stability parameter through site-directed mutagenesis (K128N substitution). This specific amino acid change increases the melting temperature and resistance to thermal denaturation while preserving the protein's ability to bind FGFR and activate downstream signaling pathways, thus maintaining biological activity
Solution Approach 2:
The patent creates a modified copy of the FGF-2 protein with the K128N substitution. This copy retains the essential structural features and binding interfaces of wild-type FGF-2 necessary for biological activity, while incorporating the stabilizing mutation to improve thermal resistance without losing functional capability
Data Source
AI summary
Thermostable FGF-2 proteins having enhanced ability to support human pluripotent stem cell cultures are provided. Also provided are methods and compositions utilizing thermostable FGF-2 proteins.